MONEAD Tracks 387 Children to Age Six Without Language Deficit

A prospective NIH-funded study of 387 six-year-old children found no measurable difference in language ability between those exposed to newer anti-seizure medications in utero and those who were not. The result, drawn from the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) cohort, appeared in JAMA Neurology on November 27, 2024, and closes a sixteen-year monitoring arc across twenty US medical centers.

Of the 387 children tested, 298 had mothers with epilepsy who continued anti-seizure therapy during pregnancy. The remaining children served as a comparison group. Researchers assessed vocabulary, verbal reasoning, and the matching of spoken words to pictures — domains that, at age six, carry more predictive weight than the same tests given at two or three.

Adam Hartman, M.D., program director at NIH's National Institute of Neurological Disorders and Stroke, framed the clinical stakes plainly: "Controlling seizures during pregnancy is an important part of prenatal care for women with epilepsy, but for years, the effects of newer anti-seizure medications on their children was unknown."

What did the cohort actually take?

Most of the pregnant participants took lamotrigine, levetiracetam, or a combination of both — the two agents that have largely displaced valproate in routine practice over the past two decades. Valproate's teratogenicity forced the move; the MONEAD authors wanted to know whether the substitutes carried their own cognitive liabilities. At six years, the answer is no, at least not at any level the study could detect.

"What makes this study meaningful is that when you assess a child at 6, the tests are a lot more sensitive than at earlier ages, especially 2-year-olds," said Kimford Meador, M.D., co-lead investigator and professor of neurology at Stanford University. "There's measurable impact on school performance and results are more predictive of adult cognitive ability."

Does this settle the dose question?

No, and the authors are careful not to claim that it does. Earlier reports from the same team noted that high maternal blood levels of levetiracetam correlated with poorer cognitive scores at ages 2, 3, and 4.5. At six, that signal attenuates. The therapeutic trade-off remains.

"We need to balance making sure there is enough medicine on board to protect the mother and her developing fetus from seizures, but not too much where we're creating risk for the child," Meador said.

Hartman placed the same point in the NIH's framing. Correlating children's cognitive scores with maternal drug concentrations, he said, "opens the door to future work and might inform better dosing strategies." A clinician reading the paper will note that the dose-response curve for levetiracetam, specifically, has not been closed.

Where does folate fit?

A secondary MONEAD analysis delivered a finding independent of epilepsy. Folate supplementation during the first twelve weeks of pregnancy — at doses at or above 4 mg per day — associated with better cognitive and behavioral outcomes at age six. The signal held across mothers with and without epilepsy. The high-dose arm showed no adverse effect in this cohort.

That detail cuts against older reports linking very high folic acid doses to long-term risk. The MONEAD authors flag the contradiction and decline to resolve it. Replication in cohorts that include less common anti-seizure drugs is the next step. The same paper found no adverse effect of anti-seizure medication exposure through breastfeeding.

What does this change for the reading room?

For the neurologist counselling a pregnant patient with epilepsy, the new MONEAD data extend the reassurance window. Lamotrigine and levetiracetam at conventional dosing produced no measurable language deficit at six years in the largest prospective cohort assembled for this question. The harder cases — valproate avoidance, levetiracetam dose ceilings, and the long tail of rarer agents — remain in front of the same investigators and their successors.

Page Pennell, M.D., chair of neurology at the University of Pittsburgh, co-led the work with Meador. NCT01730170 is the trial registration number. The follow-on question is no longer whether the babies are all right; it is how the field tightens the dial without overshooting.

Reporting by Elena Vasquez.